This study is designed to evaluate the safety and plasma concentrations of PF-06412562 in healthy volunteers following three times daily oral dosing of PF-06412562 for 14 days
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety and toleration assessed by: adverse events, supine and standing vital sign measurements, electrocardiogram (ECG) standard 12 lead, blood and urine safety laboratory tests ,CogState and C-SSRS.
Timeframe: 0-15 days
Pharmacokinetics: Cmax, Tmax, AUCÏ„ Ctrough, PTR, Rac on Cmax and AUCÏ„ t1/2, CL/F, PTR,
Timeframe: 0-15 days
CogState at followup
Timeframe: 22-25 days